Suomi - suomi - Fimea (Suomen lääkevirasto)

sankyo pharma gmbh - fel tauri siccatum,aspergillus oryzae extractum,pancreatinum - tabletti, päällystetty - useita entsyymejä (lipaasi, proteaasi jne.) sisältävät valmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

aventis pharma deutschland gmbh - onnellinen muisto, bulls haihtua,hemicellulasum,pancreatinum - tabletti - useita entsyymejä (lipaasi, proteaasi jne.) sisältävät valmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

aventis pharma deutschland gmbh - retinoli acetas,manganosi sulfas,acidum folicum,fel tauri siccatum,cupri sulfas,cholini bitartras,thiamini nitras,acidum ascorbicum,pyridoxini hydrochloridum,cobaltosi sulfas,calcii fluoridum,hesperidinum,hemicellulasum,alfa-tocopheroli acetas,pancreatinum,kalii iodidum,nicotinamidum,methioninum,ferrosi sulfas,riboflavinum,calcii pantothenas - tabletti - useita entsyymejä (lipaasi, proteaasi jne.) sisältävät valmisteet

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Suomi - suomi - Fimea (Suomen lääkevirasto)

hexal a/s - felodipine - depottabletti - 5 mg - felodipiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

hexal a/s - felodipine - depottabletti - 10 mg - felodipiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - felodipine - depottabletti - 5 mg - felodipiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - felodipine - depottabletti - 10 mg - felodipiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

holsten pharma gmbh - felodipine - depottabletti - 5 mg - felodipiini